David Dixter, Marina Carvalho Rodriguez, Lays Lima Dutra, Andrew Walker, Michael Rivkin, Catherine Leef Martin
January 24, 2026
Milbank Advises Apotea AB in Connection with Its Initial Public Offering and Nasdaq Stockholm Listing
1 min
AI-made summary
- Milbank LLP advised Apotea AB (publ) on its initial public offering and listing on Nasdaq Stockholm
- The offering closed on December 10, 2024, with shares priced at SEK 58 each, raising SEK 1.9 billion assuming the overallotment option is exercised, and valuing Apotea at approximately SEK 6 billion
- The Milbank team was led by partner David Dixter and included several associates and partners from various practice areas.
Milbank LLP advised Apotea AB (publ) in connection with its initial public offering and Nasdaq Stockholm listing. The offering, which closed on December 10, 2024, priced at SEK 58 per share, resulting in total proceeds of SEK 1.9 billion (assuming the exercise of the overallotment option) and valuing Apotea at approximately SEK 6 billion.
Apotea is Swedenâs leading online pharmacy by market share with three million active customers. With the widest assortment on the market, low prices and quick deliveries, Apotea facilitates everyday life for its three million active customers.
The Milbank team was led by Capital Markets partner David Dixter and included associates Marina Carvalho Rodriguez and Lays Lima Dutra, as well as Tax partner Andrew Walker and associate Michael Rivkin, and Alternative Investments partner Catherine Leef Martin.
Article Author
David Dixter, Marina Carvalho Rodriguez, Lays Lima Dutra, Andrew Walker, Michael Rivkin, Catherine Leef Martin
The Sponsor